Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

osteoarthritis

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

Levicept’s NT-3 inhibitor shows promise in moderate-to-severe osteoarthritis

The degenerative joint disease affects more than 32.5 million adults in the US

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

Biogen Idec building

Biogen’s Actemra biosimilar approved by FDA to treat adult and paediatric arthritis

Tofidence is now the first biosimilar referencing Actemra to gain approval from the US regulator

- PMLiVE

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

A round-up from pharma, biotech and healthcare

- PMLiVE

Setback for J&J as FDA panel turns down arthritis drug sirukumab

US regulator concerned with the drug’s safety

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

- PMLiVE

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase

- PMLiVE

J&J’s Caruso bullish on Remicade defence plans

Believes top-selling arthritis treatment will weather introduction of biosimilars in US market

- PMLiVE

GSK launches first pharma trial powered by Apple’s ResearchKit

Will use an iPhone app built using the software for a real-world study

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links